Journal of Cardiac Failure
Volume 14, Issue 6 , Pages 467-474 , August 2008

Extracellular Matrix Turnover and Inflammatory Markers Independently Predict Functional Status and Outcome in Chronic Heart Failure

  • Anca Radauceanu, MD

      Affiliations

    • Centre d'Investigation Clinique 9501, INSERM, Dommartin-lès-Toul, France
    • INSERM U684, Nancy, France
    • CHU de Nancy, Hôpital Jeanne d'Arc, Nancy, France
    • ,
  • Camille Ducki, PharmD

      Affiliations

    • Centre d'Investigation Clinique 9501, INSERM, Dommartin-lès-Toul, France
    • CHU de Nancy, Hôpital Jeanne d'Arc, Nancy, France
    • ,
  • Jean-Marc Virion, MSc

      Affiliations

    • Centre d'Investigation Clinique 9501, INSERM, Dommartin-lès-Toul, France
    • CHU de Nancy, Hôpital Jeanne d'Arc, Nancy, France
    • ,
  • Patrick Rossignol, MD, PhD

      Affiliations

    • Centre d'Investigation Clinique 9501, INSERM, Dommartin-lès-Toul, France
    • INSERM U684, Nancy, France
    • Université Henri Poincaré, Nancy, France
    • CHU de Nancy, Hôpital Brabois, Department of Cardiology, Nancy, France
    • CHU de Nancy, Hôpital Jeanne d'Arc, Nancy, France
    • ,
  • Ziad Mallat, MD, PhD

      Affiliations

    • INSERM, U689, Paris, France
    • ,
  • John McMurray, MD, FACC

      Affiliations

    • Western Infirmary, Cardiology, Glasgow, Scotland
    • ,
  • Dirk J. Van Veldhuisen, MD, FACC

      Affiliations

    • Department of Cardiology, Thoraxcenter, University Medical Centre Groningen, University of Groningen, The Netherlands
    • ,
  • Luigi Tavazzi, MD, FACC

      Affiliations

    • Fondazione IRCCS, Policlinico san Matteo, Pavia, Italy
    • ,
  • Douglas L. Mann, MD, FACC

      Affiliations

    • Baylor College of Medicine, Texas Heart Institute/St. Luke's Episcopal, Houston, Texas
    • ,
  • Josette Capiaumont-Vin, PhD

      Affiliations

    • Centre d'Investigation Clinique 9501, INSERM, Dommartin-lès-Toul, France
    • Université Henri Poincaré, Nancy, France
    • CHU de Nancy, Hôpital Jeanne d'Arc, Nancy, France
    • ,
  • Minjiang Li, MD

      Affiliations

    • INSERM U684, Nancy, France
    • Université Henri Poincaré, Nancy, France
    • ,
  • Didier Hanriot, PhD

      Affiliations

    • INSERM U684, Nancy, France
    • Université Henri Poincaré, Nancy, France
    • ,
  • Faiez Zannad, MD, PhD

      Affiliations

    • Centre d'Investigation Clinique 9501, INSERM, Dommartin-lès-Toul, France
    • INSERM U684, Nancy, France
    • Université Henri Poincaré, Nancy, France
    • CHU de Nancy, Hôpital Brabois, Department of Cardiology, Nancy, France
    • CHU de Nancy, Hôpital Jeanne d'Arc, Nancy, France
    • Corresponding Author InformationReprint requests: Professor Faiez Zannad, Centre d'Investigation Clinique (CIC) CHU-INSERM, Hôpital Jeanne d'Arc, BP 90303, F-54201 Dommartin-Les-Toul, France.

Received 16 July 2007 ,Revised 4 February 2008 ,Accepted 25 February 2008.

References 

  1. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation. 2003;108:2317–2322
  2. Ingelsson E, Arnlov J, Sundstrom J, Lind L. Inflammation, as measured by the erythrocyte sedimentation rate, is an independent predictor for the development of heart failure. J Am Coll Cardiol. 2005;45:1802–1806
  3. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002;91:988–998
  4. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107:1486–1491
  5. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000;102:3060–3067
  6. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201–1206
  7. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol. 1998;31:391–398
  8. Feldman AM, Combes A, Wagner D, Kadakomi T, Kubota T, Li YY, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol. 2000;35:537–544
  9. Mann DL. Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol. 2003;65:81–101
  10. Sivasubramanian N, Coker ML, Kurrelmeyer KM, MacLellan WR, DeMayo FJ, Spinale FG, et al. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2001;104:826–831
  11. Sun M, Chen M, Dawood F, Zurawska U, Li JY, Parker T, et al. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation. 2007;115:1398–1407
  12. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev. 1999;79:215–262
  13. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized Aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000;102:2700–2706
  14. Alla F, Kearney-Schwartz A, Radauceanu A, Das Dores S, Dousset B, Zannad F. Early changes in serum markers of cardiac extra-cellular matrix turnover in patients with uncomplicated hypertension and type II diabetes. Eur J Heart Fail. 2006;8:147–153
  15. Radauceanu A, Moulin F, Djaballah W, Marie PY, Alla F, Dousset B, et al. Residual stress ischaemia is associated with blood markers of myocardial structural remodelling. Eur J Heart Fail. 2007;9:370–376
  16. Jordan A, Roldan V, Garcia M, Monmeneu J, de Burgos FG, Lip GY, et al. Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis. J Intern Med. 2007;262:385–392
  17. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594–1602
  18. D'Armiento J. Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction. Trends Cardiovasc Med. 2002;12:97–101
  19. Mallat Z, Heymes C, Corbaz A, Logeart D, Alouani S, Cohen-Solal A, et al. Evidence for altered interleukin 18 (IL)-18 pathway in human heart failure. FASEB J. 2004;18:1752–1754
  20. Silvestre JS, Mallat Z, Tamarat R, Duriez M, Tedgui A, Levy BI. Regulation of matrix metalloproteinase activity in ischemic tissue by interleukin-10: role in ischemia-induced angiogenesis. Circ Res. 2001;89:259–264
  21. Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest. 1995;96:2304–2310
  22. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006;113:2089–2096
  23. Stumpf C, Lehner C, Yilmaz A, Daniel WG, Garlichs CD. Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure. Clin Sci (Lond). 2003;105:45–50
  24. Yin WH, Chen JW, Jen HL, Chiang MC, Huang WP, Feng AN, et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J. 2004;147:931–938
  25. Windram JD, Loh PH, Rigby AS, Hanning I, Clark AL, Cleland JG. Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. Am Heart J. 2007;153:1048–1055
  26. Diwan A, Dibbs Z, Nemoto S, DeFreitas G, Carabello BA, Sivasubramanian N, et al. Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes. Circulation. 2004;109:262–268
  27. Trescher K, Bernecker O, Fellner B, Gyongyosi M, Schafer R, Aharinejad S, et al. Inflammation and postinfarct remodeling: overexpression of IkappaB prevents ventricular dilation via increasing TIMP levels. Cardiovasc Res. 2006;69:746–754
  28. Williams TN, Zhang CX, Game BA, He L, Huang Y. C-reactive protein stimulates MMP-1 expression in U937 histiocytes through Fc[gamma]RII and extracellular signal-regulated kinase pathway: an implication of CRP involvement in plaque destabilization. Arterioscler Thromb Vasc Biol. 2004;24:61–66
  29. Jensen LT, Host NB. Collagen: scaffold for repair or execution. Cardiovasc Res. 1997;33:535–539
  30. Chapman D, Weber KT, Eghbali M. Regulation of fibrillar collagen types I and III and basement membrane type IV collagen gene expression in pressure overloaded rat myocardium. Circ Res. 1990;67:787–794
  31. Klappacher G, Franzen P, Haab D, Mehrabi M, Binder M, Plesch K, et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol. 1995;75:913–918
  32. Mukherjee D, Sen S. Alteration of collagen phenotypes in ischemic cardiomyopathy. J Clin Invest. 1991;88:1141–1146
  33. Jugdutt BI. Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways. Curr Drug Targets Cardiovasc Haematol Disord. 2003;3:1–30
  34. Cicoira M, Rossi A, Bonapace S, Zanolla L, Golia G, Franceschini L, et al. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J Card Fail. 2004;10:403–411
  35. Rossi A, Cicoira M, Golia G, Zanolla L, Franceschini L, Marino P, et al. Amino-terminal propeptide of type III procollagen is associated with restrictive mitral filling pattern in patients with dilated cardiomyopathy: a possible link between diastolic dysfunction and prognosis. Heart. 2004;90:650–654
  36. Querejeta R, Lopez B, Gonzalez A, Sanchez E, Larman M, Martinez Ubago JL, et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation. 2004;110:1263–1268
  37. Laviades C, Varo N, Fernandez J, Mayor G, Gil MJ, Monreal I, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation. 1998;98:535–540
  38. Lopez B, Gonzalez A, Querejeta R, Larman M, Diez J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol. 2006;48:89–96
  39. Dinarello CA. Interleukin-18, a proinflammatory cytokine. Eur Cytokine Netw. 2000;11:483–486
  40. Naito Y, Tsujino T, Fujioka Y, Ohyanagi M, Okamura H, Iwasaki T. Increased circulating interleukin-18 in patients with congestive heart failure. Heart. 2002;88:296–297
  41. Yamaoka-Tojo M, Tojo T, Inomata T, Machida Y, Osada K, Izumi T. Circulating levels of interleukin 18 reflect etiologies of heart failure: Th1/Th2 cytokine imbalance exaggerates the pathophysiology of advanced heart failure. J Card Fail. 2002;8:21–27
  42. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 2002;106:24–30
  43. Blankenberg S, Luc G, Ducimetiere P, Arveiler D, Ferrieres J, Amouyel P, et al. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation. 2003;108:2453–2459
  44. Michelucci A, Ricciardi G, Sofi F, Gori AM, Pirolo F, Pieragnoli P, et al. Relation of inflammatory status to major adverse cardiac events and reverse remodeling in patients undergoing cardiac resynchronization therapy. J Card Fail. 2007;13:207–210
  45. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Conlon C, Patle A, et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation. 2007;115:888–895
  46. Bonapace S, Rossi A, Cicoira M, Franceschini L, Golia G, Zanolla L, et al. Aortic distensibility independently affects exercise tolerance in patients with dilated cardiomyopathy. Circulation. 2003;107:1603–1608

 Funded by Wyeth as the sponsor of the RECOVER trial and by CIC-INSERM-CHU of Nancy for the biomarker substudy.

PII: S1071-9164(08)00081-X

doi: 10.1016/j.cardfail.2008.02.014

Journal of Cardiac Failure
Volume 14, Issue 6 , Pages 467-474 , August 2008

Article Tools

* Image Usage & Resolution